Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy Subjects
- Conditions
- Drug Interaction
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05575297
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Tuberculosis, PulmonaryHIV
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05497674
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 45
- Registration Number
- NCT05431673
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
- Conditions
- Endocarditis Infective
- Interventions
- Drug: Fusidic Acid Only Product in Oral Dose FormDrug: Fusidic Acid Only Product in Parenteral Dose Form
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 360
- Registration Number
- NCT05398679
- Locations
- 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05389722
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 54
- Registration Number
- NCT05388448
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- Conditions
- Tuberculous Meningitis
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 330
- Registration Number
- NCT05383742
- Locations
- 🇵🇪
Socios en Salud Sucursal Peru CRS (Site ID: 31985), Lima, Peru
🇵🇪Barranco CRS (Site ID:11301), Lima, Peru
🇵🇭TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981), Cavite, Philippines
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT05372367
- Locations
- 🇪🇸
Hospital Quiron. I.C.U., Barcelona, Spain
🇪🇸Fundación Jiménez Díaz, Madrid, Spain
🇪🇸CIO Clara Campal, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.